The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia

Justin M. Watts; Terrence Bradley

doi:10.1158/1078-0432.CCR-20-0462

The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia

Justin M. Watts, Terrence Bradley

Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.See related article by Wei et al., p. 3154.

Original language	English (US)
Pages (from-to)	3073-3076
Number of pages	4
Journal	Clinical cancer research : an official journal of the American Association for Cancer Research
Volume	26
Issue number	13
DOIs	https://doi.org/10.1158/1078-0432.CCR-20-0462
State	Published - Jul 1 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-20-0462

Fingerprint Dive into the research topics of 'The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this

@article{c8d9d3ef53e945328a1cfb3483fa4670,

title = "The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia",

abstract = "Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.See related article by Wei et al., p. 3154.",

author = "Watts, {Justin M.} and Terrence Bradley",

note = "Publisher Copyright: {\textcopyright}2020 American Association for Cancer Research. Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine",

year = "2020",

month = jul,

day = "1",

doi = "10.1158/1078-0432.CCR-20-0462",

language = "English (US)",

volume = "26",

pages = "3073--3076",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "13",

}

TY - JOUR

T1 - The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia

AU - Watts, Justin M.

AU - Bradley, Terrence

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.See related article by Wei et al., p. 3154.

AB - Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.See related article by Wei et al., p. 3154.

UR - http://www.scopus.com/inward/record.url?scp=85087469561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087469561&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-20-0462

DO - 10.1158/1078-0432.CCR-20-0462

M3 - Comment/debate

C2 - 32284317

AN - SCOPUS:85087469561

VL - 26

SP - 3073

EP - 3076

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -